Contact Us
Global Malignant Mesothelioma Market Report 2025

Malignant Mesothelioma Global Market Report 2025 - By Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy), By Route Of Administration (Oral, Intravenous, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies), By End-User (Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories) - Market Size, Trends, And Global Forecast 2025-2034

Malignant Mesothelioma Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : April 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Malignant Mesothelioma Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

What Is Covered Under Malignant Mesothelioma Market?

Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing.

The main types of malignant mesothelioma are chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy for malignant mesothelioma is a treatment that uses drugs to kill cancer cells, slow tumor growth, and help manage symptoms. It is often used when mesothelioma has spread beyond where surgery alone can be effective. The various routes of administration involved are oral, intravenous, injectable, and topical. The distribution channels involved are hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which hospitals, oncology clinics, Rehabilitation centers, and research laboratories use.

Malignant Mesothelioma Market Size and growth rate 2025 to 2029: Graph

What Is The Malignant Mesothelioma Market Size 2025 And Growth Rate?

The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing investments in oncology research, rise in asbestos-related litigation cases, rise in hospital investments, rise in the aging population, and grow in ai-driven drug discovery platforms.

What Is The Malignant Mesothelioma Market Growth Forecast?

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing focus on personalized medicine, rising utilization of minimally invasive surgical procedures, rising healthcare expenditure, and growing number of clinical trials. Major trends in the forecast period include advancements in immunotherapy, personalized medicine, early detection initiatives, minimally invasive surgical techniques, and regulatory approvals.

How Is The Malignant Mesothelioma Market Segmented?

The malignant mesothelioma market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy

2) By Route Of Administration: Oral, Intravenous, Injectable, Topical

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery

4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy

5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

What Is Driving The Malignant Mesothelioma Market? Increase In Clinical Research And Development Efforts Fueling The Growth Of The Market Due To Advancements In Diagnostics And Treatment Options

The increasing clinical research and development efforts are expected to drive the growth of the malignant mesothelioma market going forward. Clinical research and development (R&D) efforts involve conducting scientific studies and trials to develop new drugs, treatments, and medical devices. These efforts include testing new products' safety, efficacy, and potential side effects through controlled clinical trials. The increasing clinical research and development efforts are due to the growing demand for new and improved treatments, especially with the rising prevalence of chronic diseases and complex conditions. Research and development efforts drive malignant mesothelioma by accelerating advances in diagnostics, treatments, and targeted therapies, fostering innovative approaches to improve early detection, enhance survival rates, and develop more effective, less invasive treatment options. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials make up nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Therefore, the increasing research and development efforts are driving the growth of the malignant mesothelioma market.

Who Are The Major Players In The Global Malignant Mesothelioma Market?

Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center

What Are The Key Trends Of The Global Malignant Mesothelioma Market? Monoclonal Antibodies Drive Innovation In Malignant Mesothelioma Treatment

Major companies operating in the malignant mesothelioma market are focusing on developing advanced treatment options, such as monoclonal antibody treatments, to inhibit tumor growth and improve treatment precision. Monoclonal antibodies refer to laboratory-made proteins that mimic the immune system's ability to detect and target specific antigens, such as those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval marks Opdivo as a new treatment option for this condition, where no standard treatments were previously established. Opdivo was designated an orphan drug for this indication, highlighting its potential to address a significant medical need.

What Are Latest Mergers And Acquisitions In The Malignant Mesothelioma Market? Astrazeneca Acquires Gracell Biotechnologies To Expand Cell Therapy Portfolio For Cancer And Autoimmune Diseases

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. With this acquisition, AstraZeneca will take over all of Gracell's fully diluted share capital, including the shares represented by American depositary shares. Gracell Biotechnologies is a China-based that specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

What Is The Regional Outlook For The Global Malignant Mesothelioma Market?

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the malignant mesothelioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Malignant Mesothelioma Market?

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Malignant Mesothelioma Industry?

The malignant mesothelioma market research report is one of a series of new reports from The Business Research Company that provides malignant mesothelioma market statistics, including malignant mesothelioma industry global market size, regional shares, competitors with a malignant mesothelioma market share, detailed malignant mesothelioma market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. This malignant mesothelioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malignant Mesothelioma Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $2.63 billion
Revenue Forecast In 2034 $3.41 billion
Growth Rate CAGR of 6.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The malignant mesothelioma market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy
2) By Route Of Administration: Oral, Intravenous, Injectable, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center
Customization Scope Request for Sample
Pricing And Purchase Options Explore Purchase Options
Market Size Value In 2025 $2.63 billion
Revenue Forecast In 2034 $3.41 billion
Growth Rate CAGR of 6.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The malignant mesothelioma market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy
2) By Route Of Administration: Oral, Intravenous, Injectable, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Malignant Mesothelioma Market Characteristics

    3. Malignant Mesothelioma Market Trends And Strategies

    4. Malignant Mesothelioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Malignant Mesothelioma Growth Analysis And Strategic Analysis Framework

    5.1. Global Malignant Mesothelioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Malignant Mesothelioma Market Growth Rate Analysis

    5.4. Global Malignant Mesothelioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Malignant Mesothelioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Malignant Mesothelioma Total Addressable Market (TAM)

    6. Malignant Mesothelioma Market Segmentation

    6.1. Global Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Chemotherapy

    Radiation Therapy

    Surgery

    Immunotherapy

    Targeted Therapy

    6.2. Global Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Intravenous

    Injectable

    Topical

    6.3. Global Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    Specialty Pharmacies

    6.4. Global Malignant Mesothelioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Oncology Clinics

    Rehabilitation Centres

    Research Laboratories

    6.5. Global Malignant Mesothelioma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Alkylating Agents

    Antimetabolites

    Combination Therapy

    6.6. Global Malignant Mesothelioma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    External Beam Radiation Therapy (EBRT)

    Intensity-Modulated Radiation Therapy (IMRT)

    Stereotactic Body Radiation Therapy (SBRT)

    Proton Therapy

    6.7. Global Malignant Mesothelioma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Pleurectomy Or Decortication (P/D)

    Extrapleural Pneumonectomy (EPP)

    Cytoreductive Surgery

    Palliative Surgery

    6.8. Global Malignant Mesothelioma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Immune Checkpoint Inhibitors

    Monoclonal Antibodies

    Tumor Vaccines

    Adoptive Cell Therapy

    6.9. Global Malignant Mesothelioma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Tyrosine Kinase Inhibitors (TKIs)

    Angiogenesis Inhibitors

    Mesothelin-Targeted Agents

    Gene Therapy-Based Approaches

    7. Malignant Mesothelioma Market Regional And Country Analysis

    7.1. Global Malignant Mesothelioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Malignant Mesothelioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Malignant Mesothelioma Market

    8.1. Asia-Pacific Malignant Mesothelioma Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Malignant Mesothelioma Market

    9.1. China Malignant Mesothelioma Market Overview

    9.2. China Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Malignant Mesothelioma Market

    10.1. India Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Malignant Mesothelioma Market

    11.1. Japan Malignant Mesothelioma Market Overview

    11.2. Japan Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Malignant Mesothelioma Market

    12.1. Australia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Malignant Mesothelioma Market

    13.1. Indonesia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Malignant Mesothelioma Market

    14.1. South Korea Malignant Mesothelioma Market Overview

    14.2. South Korea Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Malignant Mesothelioma Market

    15.1. Western Europe Malignant Mesothelioma Market Overview

    15.2. Western Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Malignant Mesothelioma Market

    16.1. UK Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Malignant Mesothelioma Market

    17.1. Germany Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Malignant Mesothelioma Market

    18.1. France Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Malignant Mesothelioma Market

    19.1. Italy Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Malignant Mesothelioma Market

    20.1. Spain Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Malignant Mesothelioma Market

    21.1. Eastern Europe Malignant Mesothelioma Market Overview

    21.2. Eastern Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Malignant Mesothelioma Market

    22.1. Russia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Malignant Mesothelioma Market

    23.1. North America Malignant Mesothelioma Market Overview

    23.2. North America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Malignant Mesothelioma Market

    24.1. USA Malignant Mesothelioma Market Overview

    24.2. USA Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Malignant Mesothelioma Market

    25.1. Canada Malignant Mesothelioma Market Overview

    25.2. Canada Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Malignant Mesothelioma Market

    26.1. South America Malignant Mesothelioma Market Overview

    26.2. South America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Malignant Mesothelioma Market

    27.1. Brazil Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Malignant Mesothelioma Market

    28.1. Middle East Malignant Mesothelioma Market Overview

    28.2. Middle East Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Malignant Mesothelioma Market

    29.1. Africa Malignant Mesothelioma Market Overview

    29.2. Africa Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Malignant Mesothelioma Market Competitive Landscape And Company Profiles

    30.1. Malignant Mesothelioma Market Competitive Landscape

    30.2. Malignant Mesothelioma Market Company Profiles

    30.2.1. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. NYU Langone Health Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. The University of Chicago Medical Center Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Ono Pharmaceutical Co., Ltd. Overview, Products and Services, Strategy and Financial Analysis

    31. Malignant Mesothelioma Market Other Major And Innovative Companies

    31.1. Dana-Farber Cancer Institute

    31.2. UVA Health

    31.3. PharmaMar

    31.4. Healthcare Global Enterprises Ltd.

    31.5. Fujirebio Europe

    31.6. Cancer Healer Center

    31.7. Rosetta Genomics

    31.8. Mesothelioma UK

    31.9. The Mesothelioma Center

    31.10. Oncoplus

    31.11. Mesothelioma Research Foundation of America

    31.12. Pleural Mesothelioma Center

    31.13. Company 18

    31.14. Company 19

    31.15. Company 20

    32. Global Malignant Mesothelioma Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Malignant Mesothelioma Market

    34. Recent Developments In The Malignant Mesothelioma Market

    35. Malignant Mesothelioma Market High Potential Countries, Segments and Strategies

    35.1 Malignant Mesothelioma Market In 2029 - Countries Offering Most New Opportunities

    35.2 Malignant Mesothelioma Market In 2029 - Segments Offering Most New Opportunities

    35.3 Malignant Mesothelioma Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Malignant Mesothelioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Malignant Mesothelioma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Malignant Mesothelioma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Malignant Mesothelioma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Malignant Mesothelioma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Malignant Mesothelioma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Malignant Mesothelioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Malignant Mesothelioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: AstraZeneca Financial Performance
  • Table 81: NYU Langone Health Financial Performance
  • Table 82: Mayo Foundation for Medical Education and Research Financial Performance
  • Table 83: The University of Chicago Medical Center Financial Performance
  • Table 84: Ono Pharmaceutical Co., Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Malignant Mesothelioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Malignant Mesothelioma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Malignant Mesothelioma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Malignant Mesothelioma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Malignant Mesothelioma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Malignant Mesothelioma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Malignant Mesothelioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Malignant Mesothelioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: AstraZeneca Financial Performance
  • Figure 81: NYU Langone Health Financial Performance
  • Figure 82: Mayo Foundation for Medical Education and Research Financial Performance
  • Figure 83: The University of Chicago Medical Center Financial Performance
  • Figure 84: Ono Pharmaceutical Co., Ltd. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Malignant Mesothelioma market?

Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing. For further insights on the Malignant Mesothelioma market, request a sample here

How will the Malignant Mesothelioma market drivers and restraints affect the market dynamics? What forces will shape the Malignant Mesothelioma industry going forward?

The Malignant Mesothelioma market major growth driver - Increase In Clinical Research And Development Efforts Fueling The Growth Of The Market Due To Advancements In Diagnostics And Treatment Options. For further insights on the Malignant Mesothelioma market, request a sample here

What is the forecast market size or the forecast market value of the Malignant Mesothelioma market?

The Malignant Mesothelioma market size has grown strongly in recent years. The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing investments in oncology research, rise in asbestos-related litigation cases, rise in hospital investments, rise in the aging population, and grow in ai-driven drug discovery platforms. The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing focus on personalized medicine, rising utilization of minimally invasive surgical procedures, rising healthcare expenditure, and growing number of clinical trials. Major trends in the forecast period include advancements in immunotherapy, personalized medicine, early detection initiatives, minimally invasive surgical techniques, and regulatory approvals. For further insights on the Malignant Mesothelioma market, request a sample here

How is the Malignant Mesothelioma market segmented?

The Malignant Mesothelioma market covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories

Subsegments:
1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches For further insights on the Malignant Mesothelioma market,
request a sample here

Which region has the largest share of the Malignant Mesothelioma market? What are the other regions covered in the report?

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Malignant Mesothelioma market, request a sample here.

Who are the major players in the Malignant Mesothelioma market?

Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center . For further insights on the Malignant Mesothelioma market, request a sample here.

What are the key trends in the Malignant Mesothelioma market?

Major trends in the Malignant Mesothelioma market include Monoclonal Antibodies Drive Innovation In Malignant Mesothelioma Treatment. For further insights on the Malignant Mesothelioma market, request a sample here.

What are the major opportunities in the Malignant Mesothelioma market? What are the strategies for the Malignant Mesothelioma market?

For detailed insights on the major opportunities and strategies in the Malignant Mesothelioma market, request a sample here.

How does the Malignant Mesothelioma market relate to the overall economy and other similar markets?

For detailed insights on Malignant Mesothelioma's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Malignant Mesothelioma industry?

For detailed insights on the mergers and acquisitions in the Malignant Mesothelioma industry, request a sample here.

What are the key dynamics influencing the Malignant Mesothelioma market growth? SWOT analysis of the Malignant Mesothelioma market.

For detailed insights on the key dynamics influencing the Malignant Mesothelioma market growth and SWOT analysis of the Malignant Mesothelioma industry, request a sample here.